Hemophagocytic Lymphohistiocytosis Terminated Phase 2 / 3 Trials for Emapalumab (DB14724)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

IndicationStatusPhase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)Terminated2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03985423
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHTreatment